Related Experiment Video
Updated: Jun 10, 2026

07:27
Olfactory Assays for Mouse Models of Neurodegenerative Disease
Published on: August 25, 2014
Shortened olfactory identification testing to differentiate parkinsonian syndromes
Christoph Theyer1, Frank Jagusch1, Florian Krismer1
1Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
Parkinsonism & Related Disorders
|June 8, 2026
Summary
Three abbreviated olfactory tests, using seven or more odors, effectively differentiate Parkinson's disease (PD) from atypical parkinsonian disorders (APD), maintaining diagnostic accuracy comparable to the full Sniffin Sticks identification test (SS-I).
Area of Science:
- Neurology
- Neuroscience
- Diagnostic Medicine
Background:
- Olfactory testing is crucial for differentiating Parkinson's disease (PD) from atypical parkinsonian disorders (APD).
- Abbreviated olfactory tests exist, but lack validation in independent cohorts.
- This study evaluates abbreviated Sniffin Sticks' identification tests (SS-I) for PD vs. APD discrimination.
Purpose of the Study:
- To assess the diagnostic accuracy of abbreviated Sniffin Sticks' identification tests (SS-I) in distinguishing Parkinson's disease (PD) from atypical parkinsonian disorders (APD).
- To identify abbreviated SS-I versions that are non-inferior to the full test in an independent cohort.
Main Methods:
- Collected SS-I results from 175 PD and 90 APD patients.
- Identified 8 abbreviated SS-I versions from literature.
- Compared diagnostic accuracy (AUC) of abbreviated tests against the full SS-I using DeLong test and Monte Carlo cross-validation.
Main Results:
- The full SS-I demonstrated good diagnostic accuracy (AUC: 0.81).
- Three abbreviated SS-I versions (7, 8, or 12 odors) were non-inferior to the full test (AUCs >0.80).
- Five abbreviated versions showed lower accuracy (AUCs <0.78) and suboptimal performance.
Conclusions:
- Three abbreviated SS-I tests, utilizing seven or more odors, retain significant diagnostic value for differentiating PD from APD.
- These validated abbreviated tests offer a potentially more efficient diagnostic tool.
- Results were consistent after cross-validation, confirming generalizability.
Related Concept Videos
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

